Cari Gallman's most recent trade in Bristol-Myers Squibb Co. was a trade of 39,184 Performance Shares done . Disclosure was reported to the exchange on March 10, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Bristol-Myers Squibb | Cari Gallman | EVP, General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2026 | 39,184 | 39,184 | - | - | Performance Shares | |
| Bristol-Myers Squibb | Cari Gallman | EVP, General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2026 | 26,122 | 26,122 | - | - | Market Share Units | |
| Bristol-Myers Squibb | Cari Gallman | EVP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2026 | 5,201 | 0 | - | - | Performance Shares | |
| Bristol-Myers Squibb | Cari Gallman | EVP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2026 | 5,201 | 17,039 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb | Cari Gallman | EVP, General Counsel | Other type of transaction at price $ 0.00 per share. | 10 Mar 2026 | 2,554 | 14,485 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb | Cari Gallman | EVP, General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 60.13 per share. | 10 Mar 2026 | 1,354 | 13,131 (0%) | 0% | 60.1 | 81,416 | Common Stock, $0.10 par value |
| Bristol-Myers Squibb | Cari Gallman | EVP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2026 | 912 | 11,978 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb | Cari Gallman | EVP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2026 | 912 | 0 | - | - | Market Share Units | |
| Bristol-Myers Squibb | Cari Gallman | EVP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2026 | 867 | 12,328 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb | Cari Gallman | EVP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2026 | 867 | 867 | - | - | Market Share Units | |
| Bristol-Myers Squibb | Cari Gallman | EVP, General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 60.13 per share. | 10 Mar 2026 | 415 | 11,461 (0%) | 0% | 60.1 | 24,954 | Common Stock, $0.10 par value |
| Bristol-Myers Squibb | Cari Gallman | EVP, General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 60.13 per share. | 10 Mar 2026 | 396 | 11,838 (0%) | 0% | 60.1 | 23,811 | Common Stock, $0.10 par value |
| Bristol-Myers Squibb | Cari Gallman | EVP, General Counsel | Other type of transaction at price $ 0.00 per share. | 10 Mar 2026 | 102 | 11,876 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb | Cari Gallman | EVP, General Counsel | Other type of transaction at price $ 0.00 per share. | 10 Mar 2026 | 94 | 12,234 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb | Cari Gallman | EVP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Oct 2025 | 4,558 | 13,398 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb | Cari Gallman | EVP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Oct 2025 | 4,558 | 4,559 | - | - | Restricted Stock Units | |
| Bristol-Myers Squibb | Cari Gallman | EVP, General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 45.73 per share. | 02 Oct 2025 | 2,332 | 11,066 (0%) | 0% | 45.7 | 106,642 | Common Stock, $0.10 par value |
| Bristol-Myers Squibb | Cari Gallman | EVP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Aug 2025 | 1,061 | 1,061 | - | - | Restricted Stock Units | |
| Bristol-Myers Squibb | Cari Gallman | EVP, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Aug 2025 | 1,061 | 9,383 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb | Cari Gallman | EVP, General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 44.23 per share. | 01 Aug 2025 | 543 | 8,840 (0%) | 0% | 44.2 | 24,017 | Common Stock, $0.10 par value |
| Bristol-Myers Squibb | Cari Gallman | EVP, Corporate Affairs | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2025 | 20,084 | 20,084 | - | - | Performance Shares | |
| Bristol-Myers Squibb | Cari Gallman | EVP, Corporate Affairs | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2025 | 13,389 | 13,389 | - | - | Market Share Units | |
| Bristol-Myers Squibb | Cari Gallman | EVP, Corporate Affairs | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2025 | 5,462 | 0 | - | - | Performance Shares | |
| Bristol-Myers Squibb | Cari Gallman | EVP, Corporate Affairs | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2025 | 5,462 | 11,626 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb | Cari Gallman | EVP, Corporate Affairs | Other type of transaction at price $ 0.00 per share. | 10 Mar 2025 | 2,014 | 9,612 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb | Cari Gallman | EVP, Corporate Affairs | Payment of exercise price or tax liability using portion of securities received from the company at price $ 63.11 per share. | 10 Mar 2025 | 1,290 | 8,322 (0%) | 0% | 63.1 | 81,412 | Common Stock, $0.10 par value |
| Bristol-Myers Squibb | Cari Gallman | EVP, Corporate Affairs | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2025 | 910 | 6,136 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb | Cari Gallman | EVP, Corporate Affairs | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2025 | 910 | 912 | - | - | Market Share Units | |
| Bristol-Myers Squibb | Cari Gallman | EVP, Corporate Affairs | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2025 | 867 | 6,572 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb | Cari Gallman | EVP, Corporate Affairs | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2025 | 867 | 1,734 | - | - | Market Share Units | |
| Bristol-Myers Squibb | Cari Gallman | EVP, Corporate Affairs | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2025 | 349 | 5,368 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb | Cari Gallman | EVP, Corporate Affairs | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2025 | 349 | 0 | - | - | Market Share Units | |
| Bristol-Myers Squibb | Cari Gallman | EVP, Corporate Affairs | Payment of exercise price or tax liability using portion of securities received from the company at price $ 63.11 per share. | 10 Mar 2025 | 272 | 5,705 (0%) | 0% | 63.1 | 17,166 | Common Stock, $0.10 par value |
| Bristol-Myers Squibb | Cari Gallman | EVP, Corporate Affairs | Payment of exercise price or tax liability using portion of securities received from the company at price $ 63.11 per share. | 10 Mar 2025 | 260 | 6,164 (0%) | 0% | 63.1 | 16,409 | Common Stock, $0.10 par value |
| Bristol-Myers Squibb | Cari Gallman | EVP, Corporate Affairs | Other type of transaction at price $ 0.00 per share. | 10 Mar 2025 | 159 | 5,977 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb | Cari Gallman | EVP, Corporate Affairs | Other type of transaction at price $ 0.00 per share. | 10 Mar 2025 | 148 | 6,424 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb | Cari Gallman | EVP, Corporate Affairs | Payment of exercise price or tax liability using portion of securities received from the company at price $ 63.11 per share. | 10 Mar 2025 | 118 | 5,226 (0%) | 0% | 63.1 | 7,447 | Common Stock, $0.10 par value |
| Bristol-Myers Squibb | Cari Gallman | EVP, Corporate Affairs | Other type of transaction at price $ 0.00 per share. | 10 Mar 2025 | 24 | 5,344 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb | Cari Gallman | EVP, Corporate Affairs | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Oct 2024 | 4,558 | 6,667 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb | Cari Gallman | EVP, Corporate Affairs | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Oct 2024 | 4,558 | 9,117 | - | - | Restricted Stock Units | |
| Bristol-Myers Squibb | Cari Gallman | EVP, Corporate Affairs | Payment of exercise price or tax liability using portion of securities received from the company at price $ 53.76 per share. | 02 Oct 2024 | 1,648 | 5,019 (0%) | 0% | 53.8 | 88,596 | Common Stock, $0.10 par value |
| Bristol-Myers Squibb | Cari Gallman | EVP, Corporate Affairs | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Aug 2024 | 1,061 | 2,122 | - | - | Restricted Stock Units | |
| Bristol-Myers Squibb | Cari Gallman | EVP, Corporate Affairs | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Aug 2024 | 1,061 | 2,493 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb | Cari Gallman | EVP, Corporate Affairs | Payment of exercise price or tax liability using portion of securities received from the company at price $ 48.17 per share. | 01 Aug 2024 | 384 | 2,109 (0%) | 0% | 48.2 | 18,497 | Common Stock, $0.10 par value |
| Bristol-Myers Squibb | Cari Gallman | EVP, Corporate Affairs | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2024 | 11,029 | 11,029 | - | - | Performance Shares | |
| Bristol-Myers Squibb | Cari Gallman | EVP, Corporate Affairs | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2024 | 7,353 | 7,353 | - | - | Market Share Units | |
| Bristol-Myers Squibb | Cari Gallman | EVP, Corporate Affairs | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2024 | 2,094 | 0 | - | - | Performance Shares | |
| Bristol-Myers Squibb | Cari Gallman | EVP, Corporate Affairs | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2024 | 2,094 | 2,655 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb | Cari Gallman | EVP, Corporate Affairs | Other type of transaction at price $ 0.00 per share. | 10 Mar 2024 | 910 | 1,822 | - | - | Market Share Units | |
| Bristol-Myers Squibb | Cari Gallman | EVP, Corporate Affairs | Other type of transaction at price $ 0.00 per share. | 10 Mar 2024 | 867 | 2,601 | - | - | Market Share Units | |
| Bristol-Myers Squibb | Cari Gallman | EVP, Corporate Affairs | Other type of transaction at price $ 0.00 per share. | 10 Mar 2024 | 729 | 1,926 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb | Cari Gallman | EVP, Corporate Affairs | Payment of exercise price or tax liability using portion of securities received from the company at price $ 53.79 per share. | 10 Mar 2024 | 494 | 1,432 (0%) | 0% | 53.8 | 26,572 | Common Stock, $0.10 par value |
| Bristol-Myers Squibb | Cari Gallman | EVP, Corporate Affairs | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2024 | 349 | 349 | - | - | Market Share Units | |
| Bristol-Myers Squibb | Cari Gallman | EVP, Corporate Affairs | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2024 | 349 | 726 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb | Cari Gallman | EVP, Corporate Affairs | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2024 | 318 | 0 | - | - | Market Share Units | |
| Bristol-Myers Squibb | Cari Gallman | EVP, Corporate Affairs | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2024 | 318 | 524 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb | Cari Gallman | EVP, Corporate Affairs | Payment of exercise price or tax liability using portion of securities received from the company at price $ 53.79 per share. | 10 Mar 2024 | 105 | 561 (0%) | 0% | 53.8 | 5,648 | Common Stock, $0.10 par value |
| Bristol-Myers Squibb | Cari Gallman | EVP, Corporate Affairs | Payment of exercise price or tax liability using portion of securities received from the company at price $ 53.79 per share. | 10 Mar 2024 | 97 | 377 (0%) | 0% | 53.8 | 5,218 | Common Stock, $0.10 par value |
| Bristol-Myers Squibb | Cari Gallman | EVP, Corporate Affairs | Other type of transaction at price $ 0.00 per share. | 10 Mar 2024 | 60 | 666 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb | Cari Gallman | EVP, Corporate Affairs | Other type of transaction at price $ 0.00 per share. | 10 Mar 2024 | 50 | 474 (0%) | 0% | 0 | Common Stock, $0.10 par value |